Bhidayasiri Roongroj
Department of Neurology, UCLA Medical Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
Neurologist. 2006 Mar;12(2):74-85. doi: 10.1097/01.nrl.0000195831.46000.2d.
Dystonia refers to a syndrome of sustained muscle contractions, frequently causing twisting and repetitive movements or abnormal postures. Although age at onset, anatomic distribution, and family history are essential elements in the evaluation of dystonia, new classification increasingly relies on etiologic and genetic data. In recent years, much progress has been made on the genetics of various forms of dystonia and its pathophysiology underlying the clinical signs. The treatment of dystonia has continued to evolve to include newer medications, different forms of botulinum toxin, and various surgical procedures.
In this article, the author reviewed and summarized the history of dystonia, its evolving classification, and recent genetic data, as well as its clinical investigation and treatment.
Recent advances in molecular biology have led to the discovery of novel dystonia genes and loci, updating classification schemes, and better understanding of underlying pathophysiology. Treatment strategies for dystonia have significantly been updated with the introduction of different forms of botulinum toxin therapy, new pharmacologic agents, and most recently pallidal deep brain stimulation. A systematic approach to the diagnosis and treatment evaluation of dystonic patients provides optimal care for long-term management.
肌张力障碍是指一种持续性肌肉收缩综合征,常导致扭曲和重复性动作或异常姿势。尽管发病年龄、解剖分布和家族史是评估肌张力障碍的重要因素,但新的分类越来越依赖病因学和遗传学数据。近年来,在各种形式肌张力障碍的遗传学及其临床体征背后的病理生理学方面取得了很大进展。肌张力障碍的治疗也在不断发展,包括更新的药物、不同形式的肉毒杆菌毒素和各种外科手术。
在本文中,作者回顾并总结了肌张力障碍的历史、不断演变的分类、近期的遗传学数据以及其临床研究和治疗。
分子生物学的最新进展导致发现了新的肌张力障碍基因和基因座,更新了分类方案,并更好地理解了潜在的病理生理学。随着不同形式肉毒杆菌毒素疗法、新的药物制剂以及最近苍白球深部脑刺激的引入,肌张力障碍的治疗策略有了显著更新。对肌张力障碍患者进行诊断和治疗评估的系统方法可为长期管理提供最佳护理。